close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGM Biosciences, Inc. - Common Stock (NQ:IGMS)

1.270 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IGM Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at Two Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
Presentations highlight data from across all oncology pipeline programs 
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – 
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations 
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences to Present at Three Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
News headline image
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From IGM Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today